Robert James Peach
41Patents
12h-index
34Co-inventors
81Inventor score
Filing activity: Apr 15, 1994 → Feb 3, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5773253A | MYPPPY variants of CTL A4 and uses thereof | Chemistry; Metallurgy | 95 | Expired |
| US6965018B2 | Antibodies directed to B7-related polypeptide, BSL-2 | Emerging Cross-Sectional Technologies | 88 | Expired |
| US6090914A | CTLA4/CD28Ig hybrid fusion proteins and uses thereof | Chemistry; Metallurgy | 79 | Expired |
| US7304033B2 | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | Chemistry; Metallurgy | 66 | Expired |
| US7279567B2 | Polynucleotides-encoding B7-related polypeptide, BSL2-L165-35B | Emerging Cross-Sectional Technologies | 61 | Expired |
| US7358354B2 | Polynucleotides encoding BSL3 | Emerging Cross-Sectional Technologies | 55 | Expired |
| US7094874B2 | Soluble CTLA4 mutant molecules | Chemistry; Metallurgy | 46 | Expired |
| US7455835B2 | Methods for treating immune system diseases using a soluble CTLA4 molecule | Chemistry; Metallurgy | 43 | Expired |
| US7368554B2 | Polynucleotides encoding BSL2v1c2-Ig | Emerging Cross-Sectional Technologies | 40 | Expired |
| US7723479B2 | BSL3 polypeptides | Emerging Cross-Sectional Technologies | 26 | Active |
| US7105166B1 | Soluble CTLA4 mutant molecules and uses thereof | Chemistry; Metallurgy | 21 | Expired |
| US7439230B2 | Methods of treatment using CTLA4 mutant molecules | Chemistry; Metallurgy | 18 | Expired |
| US7700556B2 | Methods of treatment using CTLA4 mutant molecules | Chemistry; Metallurgy | 12 | Active |
| US9409970B2 | Polynucleotides encoding BSL2v2c2 | Emerging Cross-Sectional Technologies | 12 | Active |
| US8497247B2 | Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule | Chemistry; Metallurgy | 11 | Active |
| US7829534B2 | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | Chemistry; Metallurgy | 10 | Active |
| US8227420B2 | Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID | Chemistry; Metallurgy | 9 | Active |
| US8148332B2 | Method for treating a rheumatic disease using a soluble TLA4 molecule | Chemistry; Metallurgy | 8 | Active |
| US8354513B2 | Polynucleotides encoding BSL2vcvc-lg | Emerging Cross-Sectional Technologies | 8 | Active |
| US8362048B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | Chemistry; Metallurgy | 7 | Active |
| US8722632B2 | Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule | Chemistry; Metallurgy | 7 | Active |
| US9758565B2 | Methods of treatment using CTLA4 mutant molecules | Chemistry; Metallurgy | 5 | Active |
| US8785398B2 | Methods of treatment using CTLA4 mutant molecules | Chemistry; Metallurgy | 5 | Active |
| US7807786B2 | BSL2v1c2 polypeptides | Emerging Cross-Sectional Technologies | 5 | Active |
| US8703718B2 | Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule | Chemistry; Metallurgy | 5 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.